Print this page    •   Back to Web version of article

U.S. News
FDA Approves Hepatitis C Treatment Ribasphere

December 9, 2005

The Food and Drug Administration has approved the hepatitis C treatment Ribasphere, co-manufactured by Par Pharmaceutical Cos. and Three Rivers Pharmaceuticals LLC, the companies said Monday. FDA approved Ribasphere, which uses the active ingredient ribavirin, in 200 mg, 400 mg and 600 mg tablets for use with interferon alfa-2a to treat hepatitis C.

Back to other news for December 9, 2005

Excerpted from:
Associated Press
12.05.2005



This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art25514.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.